IRA revisions now exempt multi-indication orphan drugs from price negotiations, improving lifecycle economics and encouraging ...

RM100 today! T&Cs apply. Mr. Bobby Sheng, Chairman of Bora Group, stated, "2025 represented a pivotal year for Bora Group.

Rapid Micro Biosystems, Inc. sees strong FY25 revenue growth from Growth Direct placements, but losses persist. Click for ...

Twelve months ago, drugmakers came roaring into 2025, fueled by a massive year of growth that peaked in the fourth quarter of ...

Top 30 pharma companies post 12% revenue growth in first nine months, net profit up only by 2.8%: Sanjay Pingle, Mumbai Friday, March 13, 2026, 08:00 Hrs [IST] The aggregate finan ...

In December 2025, the FDA approved the first-ever GLP-1 pill for chronic weight management - Novo Nordisk’s oral formulation ...

Artificial intelligence (AI) has high strategic importance within biopharma marketing, sales, and commercialisation and nearly six in 10 pharma leaders report seeing 2x ROI from AI initiatives within ...

India's pharmaceutical market grew 11% in February 2026, driven by strong anti-diabetic, cardiac and anti-infective therapy sales, with Mounjaro leading as the top-selling drug by value ...

In this week’s episode of “The Top Line,” we take a deep dive into the fourth-quarter performance of the biopharma industry ...

Merck & Co.’s landmark cancer drug is still the industry’s bestseller despite the rise of GLP-1s — and other topics on our ...

Under the deal, Alfasigma will gain rights to develop, manufacture and commercialize linerixibat.

Pakistan's pharmaceutical industry, valued at Rs. 748 billion, faces challenges with API imports. Localizing API production could enhance economic stability and healthcare affordability.